Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: Comparison of extended-release oxycodone and OROS hydromorphone

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2333-2345

  Ward, Alexandra ^a   Bozkaya, Duygu ^a   Fleischmann, Jochen ^c   Dubois, Dominique ^d   Sabatowski, Rainer ^e   Caro, J Jaime ^a,b  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c JANSSEN CILAG GMBH   (Germany)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cost effectiveness analysis; Opioid; OROS Hydromorphone; Osteoarthritis; Oxycodone; Pain

Indexed keywords

HYDROMORPHONE; OXYCODONE;

ADULT; AGED; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC ASPECT; FEMALE; HEALTH CARE; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; CHRONIC DISEASE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; GERMANY; HUMANS; HYDROMORPHONE; OSTEOARTHRITIS; OXYCODONE; PAIN; SLEEP; TREATMENT OUTCOME;

EID: 35648990051     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219643     Document Type: Article

References (45)

1. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39
2. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006;25:S22-9
3. Arzneimittelkommission der Deutschen Ärzteschaft, Degenerative Gelenkerkrankungen, AVP-Sonderheft, 2. Auflage, 2001
4. Casarett D, Karlawish J, Sankar P, et al. Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain? Pain Med 2001;2:309-16
5. Menefee LA, Cohen MJ, Anderson WR, et al. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. Pain Med 2000;1:156-72
6. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
7. Gupta S, Sathyan G. Providing constant analgesia with OROS® Hydromorphone. J Pain Symptom Manage 2007;33(2 Suppl):S19-24
8. Wallace MS, Thipphawong J. Clinical trial results with OROS® Hydromorphone. J Pain Symptom Manage 2007;33(2 Suppl):S25-32
9. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32
10. McEwan P, Baboolal K, Conway P, et al. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation. United Kingdom. Clin Ther 2005;27:1834-46
11. McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9
12. Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002;5:259-67
13. Huybrechts KF, Caro JJ, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549-61
14. Caro J, Guo S, Ward A, et al. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Curr Med Res Opin 2006;22:171-9
15. Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23 Suppl 1:17-33
16. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA. 3rd edn. Boston: McGraw-Hill, 2003
17. Federal Statistical Office: Statistics Yearbook 2004 for the Federal Republic of Germany. Stuttgart: Metzler Poeschel, 2004
18. Schneider S, Schmitt G, Mau H, et al. Prevalence and correlates of osteoarthritis in Germany. Representative data from the First National Health Survey. Orthopade 2005;34:782-90
19. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available from http://www.mortality.org or www.humanmortality.de [Last accessed 18 Nov 2005]
20. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-7
21. Lawlor P, Turner K, Hanson J, et al. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997;72:79-85
22. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23:355-68
23. Summary of product characteristics. Oxygesic 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Fachinformation, April 2006
24. Summary of product characteristics. Jurnista, Fachinformation, June 2006
25. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 2005;71:451-60
26. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94
27. Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 2003;9:223-31
28. Kosinski M, J Schein J, Kavanagh S. Health-related quality-of-life (HRQoL) outcomes for patients with chronic osteoarthritis (OA) pain of the hip or knee treated with once-daily OROS® hydromorphone versus ER oxycodone #: 818. 25th Annual Scientific Meeting of the American Pain Society, San Antonio, Texas, 3-6 May, 2006
29. Frei A, Andersen S, Hole P, et al. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003;17:5-26
30. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomized trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51
31. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
33. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26:1026-48
34. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 2005;12:106-12
35. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
36. Yang M, Dubois D, Kosinski M, et al. Mapping the MOS Sleep Scale Scores to the SF-6D Utility Index. Curr Med Res Opin 2007;23:2269-82
37. Rote Liste. Available from http://www.roteliste.de [Last accessed 12 April 2006]
38. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
39. Greiner W, Lehmann K, Earnshaw S, et al. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 2006;7:290-6
40. Lehmann K, Radbruch L, Gockel HH, et al. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur J Health Econom 2002;3:111-9
41. Neighbors DM, Bell TJ, Wilson J, et al. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001;21:129-43
42. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics 2006;24:355-71
43. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000;17:461-77
44. EBM 2000 plus. Available from http://www.kbv.de [Last accessed 12 April 2006]
45. Medizincontrolling/DRG Research Group. Available from http://drg.uni-muenster.de [Last accessed 12 April 2006]